Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Statera Biopharma Inc (STAB)

Statera Biopharma Inc (STAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 5
  • Shares Outstanding, K 53,300
  • Annual Sales, $ 1,490 K
  • Annual Income, $ -101,850 K
  • EBIT $ -31 M
  • EBITDA $ -31 M
  • 60-Month Beta 0.09
  • Price/Sales 0.00
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.07
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 01/01/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0001 unch
on 12/20/24
0.1251 -99.92%
on 12/02/24
unch (unch)
since 11/20/24
3-Month
0.0001 unch
on 12/20/24
0.1251 -99.92%
on 12/02/24
unch (unch)
since 09/20/24
52-Week
0.0001 unch
on 12/20/24
0.1251 -99.92%
on 12/02/24
-0.0004 (-80.00%)
since 12/20/23

Most Recent Stories

More News
Statera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting Firm

FORT COLLINS, Colo., June 14, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a biopharmaceutical...

STAB : 0.0001 (unch)
Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-Q Filing

FORT COLLINS, Colo., May 23, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating...

STAB : 0.0001 (unch)
Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products

Statera expects to acquire option to license Lay Sciences products for respiratory & gastrointestinal disorders ...

STAB : 0.0001 (unch)
Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone

FORT COLLINS, Colo., April 27, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a leading biopharmaceutical company creating...

STAB : 0.0001 (unch)
IMUN : 0.0930 (-7.00%)
Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-K Filing

FORT COLLINS, Colo., April 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating...

STAB : 0.0001 (unch)
Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod

FORT COLLINS, Colo., April 13, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating...

STAB : 0.0001 (unch)
COEP : 0.1415 (-2.08%)
Statera Biopharma, Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022

Live Conference Call and Webcast at 5:30 p.m. ET FORT COLLINS, Colo., March 28, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB) (the...

STAB : 0.0001 (unch)
Statera Biopharma Announces Closing of $5.7 Million Underwritten Public Offering

FORT COLLINS, Colo., March 24, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading...

STAB : 0.0001 (unch)
Statera Biopharma Announces Pricing of $5.7 Million Underwritten Public Offering

FORT COLLINS, Colo., March 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading...

STAB : 0.0001 (unch)
CORRECTION -- Statera Biopharma Announces Proposed Underwritten Public Offering

FORT COLLINS, Colo., March 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading...

STAB : 0.0001 (unch)

Business Summary

Statera BioPharma is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Statera BioPharma, formerly known...

See More

Key Turning Points

3rd Resistance Point 0.0001
2nd Resistance Point 0.0001
1st Resistance Point 0.0001
Last Price 0.0001
1st Support Level 0.0001
2nd Support Level 0.0001
3rd Support Level 0.0001

See More

52-Week High 0.1251
Fibonacci 61.8% 0.0773
Fibonacci 50% 0.0626
Fibonacci 38.2% 0.0479
Last Price 0.0001
52-Week Low 0.0001

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar